Alpha Tau Medical reports Tuesday after the bell, entering the print off a sharp rally that has now stretched to 14% over the past week and roughly 7% on the month, with the stock at $13.60.
The most telling pre-earnings signal isn't positioning — it's the CFO's behaviour. Raphi Levy sold shares in at least ten separate transactions between late June and early July, offloading more than 112,000 net shares over 90 days for aggregate proceeds north of $1.27 million. The sales ran across a rising price band, from roughly $9.47 to $14.00 per share. Each transaction carried a low significance score, consistent with a scheduled plan, but the volume and frequency heading directly into the earnings window are worth noting.
Short positioning tells a more nuanced story. Bears have built a meaningful position — short interest has climbed 66% over the past month to 3.6% of the free float — but the lending market is nowhere near distressed. Availability has loosened sharply this week, recovering to roughly 72%, up from as low as 25% in early August. Cost to borrow has also eased slightly from mid-week highs, now running near 10.4%, after touching 11.2% on August 6. The ORTEX short score of 61.9 and a short-score factor rank in the 12th percentile both flag that shorts have a meaningful presence, but the borrow market is not signalling a squeeze dynamic into the print.
Options traders are leaning incrementally more cautious. The put/call ratio has drifted up to 0.22, about 1.6 standard deviations above its 20-day average of 0.18 — modest defensive hedging, not alarm. The backdrop for the debate between bulls and bears is well-defined: HC Wainwright has reiterated Buy with a $15 target twice in July alone, while Barclays lifted its Overweight target to $17 in early June after initiating coverage. The bull case centres on Alpha DaRT's clinical momentum and the Tolmar prostate cancer partnership as a revenue pathway. The bear case is clinical-stage risk in concentrated form — a single regulatory setback could undercut the entire valuation, which already runs at deeply negative earnings and EV/EBITDA multiples consistent with a pre-profit biotech. Piper Sandler's Neutral rating with a $8 target is the outlier, a reminder that not every analyst is buying into the YTD momentum story. The EPS surprise factor rank of 91st percentile is a genuine positive, suggesting the company has a track record of beating modest expectations.
The print will ultimately test whether Alpha DaRT's clinical progress and partnership news can justify a stock that has doubled in 2026 — and whether the momentum that carried the stock 14% higher this week was front-running good news or running ahead of it.
See the live data behind this article on ORTEX.
Open DRTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
